Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01851096 · ClinicalTrials.gov registry record · Phase 1
Safety and Pharmacology Study of SNX-5422 in Subjects With Resistant Lung Adenocarcinoma
A Phase 1 study of Cancer, sponsored by Esanex.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
- 2
- Study locations
NCT01851096 is a Phase 1 study of Cancer that has completed, run by Esanex. The registered enrollment target is 17 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT01851096, a Phase 1 study of Cancer, has completed, sponsored by Esanex.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
- 2
- Study locations
Study Summary
Heat shock protein 90 (Hsp90) is a chemical in the body that is involved in the promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90.
Conditions Studied
Interventions
- DRUG SNX-5422
Study Locations (2)
District of Columbia
- Georgetown University Medical Center - Washington D.C.
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2013-03 |
| Est. Completion | 2016-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01851096
The ClinicalTrials.gov registry entry for NCT01851096 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (100% lower). The listed sponsor is Esanex, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which SNX-5422 is the first listed.
NCT01851096 reports 2 study locations spanning 2 distinct geographic areas - top geographies include District of Columbia, New York.
Frequently Asked Questions
What is clinical trial NCT01851096 about?
NCT01851096 is a clinical study titled "Safety and Pharmacology Study of SNX-5422 in Subjects With Resistant Lung Adenocarcinoma". Heat shock protein 90 (Hsp90) is a chemical in the body that is involved in the promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90.
What is the current status of trial NCT01851096?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2013-03. Estimated completion is 2016-08.
What conditions does trial NCT01851096 study?
This clinical trial studies the following conditions: Cancer.
What interventions are being tested in trial NCT01851096?
The interventions under investigation include: SNX-5422 (DRUG).
Who is sponsoring clinical trial NCT01851096?
This trial is sponsored by Esanex, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01851096 being conducted?
This trial has 2 study locations across District of Columbia, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Impact of Daily Oral Cannabis Doses in Patients With Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.